- Home
- NXDT vs LRMR Comparison
NXDT vs LRMR Comparison
Compare NXDT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- LRMR
- Stock Information
- Founded
- NXDT 2012
- LRMR N/A
- Country
- NXDT United States
- LRMR United States
- Employees
- NXDT N/A
- LRMR N/A
- Industry
- NXDT Investment Managers
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- NXDT Finance
- LRMR Health Care
- Exchange
- NXDT Nasdaq
- LRMR Nasdaq
- Market Cap
- NXDT 156.8M
- LRMR 183.8M
- IPO Year
- NXDT N/A
- LRMR N/A
- Fundamental
- Price
- NXDT $3.49
- LRMR $2.24
- Analyst Decision
- NXDT
- LRMR Strong Buy
- Analyst Count
- NXDT 0
- LRMR 9
- Target Price
- NXDT N/A
- LRMR $19.00
- AVG Volume (30 Days)
- NXDT 133.6K
- LRMR 1.4M
- Earning Date
- NXDT 01-01-0001
- LRMR 04-30-2025
- Dividend Yield
- NXDT 9.66%
- LRMR N/A
- EPS Growth
- NXDT N/A
- LRMR N/A
- EPS
- NXDT 0.99
- LRMR N/A
- Revenue
- NXDT N/A
- LRMR N/A
- Revenue This Year
- NXDT N/A
- LRMR N/A
- Revenue Next Year
- NXDT N/A
- LRMR N/A
- P/E Ratio
- NXDT $6.41
- LRMR N/A
- Revenue Growth
- NXDT N/A
- LRMR N/A
- 52 Week Low
- NXDT $5.89
- LRMR $1.61
- 52 Week High
- NXDT $13.07
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- NXDT 40.92
- LRMR 47.46
- Support Level
- NXDT $3.41
- LRMR $2.03
- Resistance Level
- NXDT $3.70
- LRMR $3.07
- Average True Range (ATR)
- NXDT 0.14
- LRMR 0.30
- MACD
- NXDT 0.01
- LRMR 0.01
- Stochastic Oscillator
- NXDT 16.67
- LRMR 31.12
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.